Trademark: 88193779
Word
ABIDE
Status
Dead
Status Code
606
Status Date
Monday, August 1, 2022
Serial Number
88193779
Mark Type
4000
Filing Date
Wednesday, November 14, 2018
Published for Opposition
Tuesday, April 30, 2019
Abandoned Date
Monday, August 1, 2022

Trademark Owner History
H. LUNDBECK A-S -
LUNDBECK LA JOLLA RESEARCH CENTER, INC. - 1st New Owner After Publication
Abide Therapeutics, Inc. - Owner At Publication

Classifications
42 Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of treating diseases involving lipid signaling pathways; research and development in pharmacology for the purpose of treating diseases involving the signaling pathways of the central nervous system; medical research for use in treating central nervous system disorders; pharmaceutical research for treating acromegaly, neuroendocrine tumors, Cushing's Disease, hyperinsulinism, and chronic pain; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, bone, respiratory, central nervous system, endocrinological, circulatory, gastroenterological, digestive, hormonal, diabetic, muscular, rheumatic, immune system, ocular and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; pharmaceutical research in the field of enzymes that employ hyper-nucleophilic active-site residues for catalysis, namely, serine, threonine and cysteine hydrolases, proteases, and acyl transferases; pharmaceutical research in the fields of immunology, namely, rheumatology, oncology, namely, immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology, namely, fertility, infectiology, namely, virology, ophthalmology, hepatology, neurology, geriatrics, laboratory medicine, clinical diagnostics, genetics and phenomics, pathology and forensics, proteomics, veterinary medicine and diagnostics, and pharmaceutical research tool development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using enzymes that employ hyper-nucleophilic active-site residues for catalysis, namely, serine, threonine and cysteine hydrolases, proteases, and acyl transferases for use in drug development; pharmaceutical research, namely, research relating to enzymes that employ hyper-nucleophilic active-site residues for catalysis, namely, serine, threonine and cysteine hydrolases, proteases, and acyl transferases for improving pharmacological properties; pharmaceutical research, namely, research relating to enzymes that employ hyper-nucleophilic active-site residues for catalysis, namely, serine, threonine and cysteine hydrolases, proteases, and acyl transferases for use in connection with a wide variety of therapeutic areas

Trademark Events
Aug 1, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Aug 1, 2022
Abandonment - No Use Statement Filed
Dec 4, 2021
Notice Of Approval Of Extension Request E-Mailed
Dec 3, 2021
Sou Extension 5 Granted
Nov 23, 2021
Sou Extension 5 Filed
Dec 3, 2021
Case Assigned To Intent To Use Paralegal
Nov 23, 2021
Sou Teas Extension Received
Nov 16, 2021
Teas Change Of Correspondence Received
Nov 16, 2021
Teas Withdrawal Of Attorney Received-Firm Retains
Nov 16, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Nov 16, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 28, 2021
Notice Of Approval Of Extension Request E-Mailed
May 26, 2021
Sou Extension 4 Granted
May 26, 2021
Sou Extension 4 Filed
May 26, 2021
Sou Teas Extension Received
Dec 8, 2020
Notice Of Approval Of Extension Request E-Mailed
Dec 4, 2020
Sou Extension 3 Granted
Dec 4, 2020
Sou Extension 3 Filed
Dec 4, 2020
Sou Teas Extension Received
Jun 11, 2020
Notice Of Approval Of Extension Request E-Mailed
Jun 9, 2020
Sou Extension 2 Granted
Jun 9, 2020
Sou Extension 2 Filed
Jun 9, 2020
Sou Teas Extension Received
Jun 8, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Jun 8, 2020
Teas Change Of Correspondence Received
Jun 8, 2020
Teas Change Of Domestic Representatives Address
Jun 8, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 8, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jun 8, 2020
Teas Change Of Owner Address Received
Apr 29, 2020
Automatic Update Of Assignment Of Ownership
Dec 19, 2019
Notice Of Approval Of Extension Request E-Mailed
Dec 17, 2019
Sou Extension 1 Granted
Dec 17, 2019
Sou Extension 1 Filed
Dec 17, 2019
Sou Teas Extension Received
Oct 9, 2019
Automatic Update Of Assignment Of Ownership
Jun 25, 2019
Noa E-Mailed - Sou Required From Applicant
Apr 30, 2019
Official Gazette Publication Confirmation E-Mailed
Apr 30, 2019
Published For Opposition
Apr 10, 2019
Notification Of Notice Of Publication E-Mailed
Mar 22, 2019
Law Office Publication Review Completed
Mar 22, 2019
Assigned To Lie
Feb 27, 2019
Approved For Pub - Principal Register
Feb 27, 2019
Examiner's Amendment Entered
Feb 27, 2019
Notification Of Examiners Amendment E-Mailed
Feb 27, 2019
Examiners Amendment E-Mailed
Feb 27, 2019
Examiners Amendment -Written
Feb 19, 2019
Assigned To Examiner
Dec 11, 2018
New Application Office Supplied Data Entered
Nov 17, 2018
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24